| Literature DB >> 33192904 |
Giacomo Rossettini1,2, Tommaso Geri1, Alvisa Palese3, Chiara Marzaro1, Mattia Mirandola1, Luana Colloca4,5, Mirta Fiorio6, Andrea Turolla7, Mattia Manoni1, Marco Testa1.
Abstract
OBJECTIVE: The aim of this study was to investigate the knowledge of orthopedic manual therapists (OMTs) regarding context factors (CFs) capable of triggering nocebo effects during the treatment and how this knowledge is related to their socio-demographic features.Entities:
Keywords: conditioning; contextual factors; expectation; nocebo effect; pain; physiotherapy (MeSH); placebo effects; survey
Year: 2020 PMID: 33192904 PMCID: PMC7606996 DOI: 10.3389/fpsyg.2020.582174
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Socio-demographic variables.
| Demography | Values | 95% CI |
| 31.0 (7.1) | 30.5–31.5 | |
| 7.4 (6.3) | 7.0–7.8 | |
| Male | 473 (59.8) | 56.3–63.2 |
| Female | 318 (40.2) | 36.8–43.7 |
| North | 561 (70.9) | 67.6–74.0 |
| Center | 161 (20.4) | 17.6–23.4 |
| South | 69 (8.7) | 6.9–11.0 |
| Private health care settings | 676 (85.5) | 82.8-87.8 |
| Public health care settings | 115 (14.5) | 12.2-17.2 |
| Freelance professional | 569 (71.9) | 68.6–75.0 |
| Employee | 222 (28.1) | 25.0–31.4 |
| Outpatient clinic | 607 (76.7) | 73.6–79.6 |
| Hospital | 123 (15.5) | 13.1–18.3 |
| Residential care (nursing home) | 61 (7.7) | 6.0–9.9 |
| Adults | 646 (81.7) | 78.8–84.3 |
| Older people | 134 (16.9) | 14.4–19.8 |
| Pediatrics | 11 (1.4) | 0.7–2.6 |
| Musculoskeletal | 718 (90.8) | 88.5–92.7 |
| Neurological | 57 (7.2) | 5.5–9.3 |
| Cardiorespiratory | 11 (1.4) | 0.7–2.6 |
| Oncological | 3 (0.4) | 0.1–1.2 |
| Uro-gynecological | 2 (0.3) | 0.0–1.0 |
| 1–15 | 18 (2.3) | 1.4–3.6 |
| 16–30 | 175 (22.1) | 19.3–25.2 |
| 31–45 | 433 (54.7) | 51.2–58.2 |
| 46–60 | 146 (18.5) | 15.8–21.4 |
| >60 | 19 (2.4) | 1.5–3.8 |
Beliefs about CFs as triggers of nocebo-related effects.
| Likert score mean (95% CI) | 4 n (%); 95% CI | 3 n (%); 95% CI | 2 n (%); 95% CI | 1 n (%); 95% CI | 0 n (%); 95% CI | |
| 2.6 (2.6–2.7) | 136 (17.2); 14.7–20.0 | 360 (45.5); 42.0–49.1 | 207 (26.2); 23.2–29.4 | 47 (5.9); 4.4–7.9 | 41 (5.2); 3.8–7.0 | |
| 1.6 (1.5–1.7) | 15 (1.9); 1.1–3.2 | 116 (14.7); 12.3–17.4 | 284 (35.9); 32.6–39.4 | 296 (37.4); 34.1–40.9 | 80 (10.1); 8.1–12.5 | |
| 3.1 (3.0–3.1) | 279 (35.3); 32.0–38.7 | 373 (47.1); 43.6–50.7 | 87 (11.0); 8.9–13.4 | 19 (2.4); 1.5–3.8 | 33 (4.2); 2.9–5.9 | |
| 3.3 (3.2–3.4) | 426 (53.9); 50.3–57.4 | 271 (34.3); 31.0–37.7 | 42 (5.3); 3.9–7.2 | 18 (2.3); 1.4–3.6 | 34 (4.3); 3.0–6.0 | |
| 3.2 (3.1–3.2) | 343 (43.4); 39.9–46.9 | 314 (39.7); 36.3–43.2 | 89 (11.2); 9.2–13.7 | 5 (0.6); 0.2–1.6 | 40 (5.1); 3.7–6.9 | |
| 3.1 (3.0–3.1) | 298 (37.7); 34.3–41.2 | 334 (42.2); 38.8–45.8 | 98 (12.4); 10.2–14.9 | 24 (3.0); 2.0–4.5 | 37 (4.7); 3.4–6.5 | |
| 2.7 (2.6–2.8) | 167 (21.1); 18.3–24.2 | 345 (43.6); 40.1–47.2 | 197 (24.9); 22.0–28.1 | 41 (5.2); 3.8–7.0 | 41 (5.2); 3.8–7.0 | |
| 3.3 (3.3–3.4) | 373 (47.1); 43.6–50.7 | 316 (39.9); 36.5–43.5 | 90 (11.4); 9.3–13.8 | 11 (1.4); 0.7–2.5 | 1 (0.1); 0.0–0.8 | |
| 2.5 (2.4–2.5) | 95 (12.0); 9.9–14.5 | 324 (41.0); 37.5–44.5 | 267 (33.7); 30.5–37.2 | 68 (8.6); 6.8–10.8 | 37 (4.7); 3.4–6.4 | |
| 1.9 (1.9–2.0) | 37 (4.7); 3.4–6.4 | 187 (23.6); 20.7–26.8 | 319 (40.3); 36.9–43.8 | 196 (24.8); 21.8–28.0 | 52 (6.6); 5.0–8.6 | |
| 2.5 (2.5–2.6) | 158 (20.0); 17.3–23.0 | 291 (36.8); 33.4–40.3 | 216 (27.3); 24.3–30.6 | 83 (10.5); 8.5–12.9 | 43 (5.4); 4.0–7.3 | |
| 1.8 (1.7–1.8) | 27 (3.4); 2.3–5.0 | 150 (19.0); 16.3–21.9 | 300 (37.9); 34.5–41.4 | 235 (29.7); 26.6–33.0 | 79 (10.0); 8.0–12.3 | |
| 2.3 (2.2–2.4) | 38 (4.8); 3.5–6.6 | 287 (36.3); 32.9–39.8 | 346 (43.7); 40.3–47.3 | 110 (13.9); 11.6–16.6 | 10 (1.3); 0.6–2.4 | |
| 2.1 (2.0–2.2) | 49 (6.2); 4.7–8.2 | 233 (29.5); 26.3–32.8 | 314 (39.7); 36.3–43.2 | 144 (18.2); 15.6–21.1 | 51 (6.4); 4.9–8.4 | |
| 1.6 (1.6–1.7) | 18 (2.3); 1.4–3.6 | 121 (15.3); 12.9–18.0 | 281 (35.5); 32.2–39.0 | 301 (38.0); 34.7–41.5 | 70 (8.8); 7.0–11.1 | |
| 2.6 (2.5–2.7) | 148 (18.7); 16.1–21.6 | 317 (40.1); 36.7–43.6 | 217 (27.4); 24.4–30.7 | 73 (9.2); 7.3–11.5 | 36 (4.5); 3.2–6.3 | |
| 2.6 (2.5–2.7) | 152 (19.2); 16.6–22.2 | 334 (42.2); 38.8–45.8 | 204 (25.8); 22.8–29.0 | 58 (7.3); 5.7–9.4 | 43 (5.4); 4.0–7.3 | |
| 2.4 (2.4–2.5) | 96 (12.1); 10.0–14.7 | 321 (40.6); 37.1–44.1 | 242 (30.6); 27.4–34.0 | 92 (11.6); 9.5–14.1 | 40 (5.1); 3.7–6.9 | |
| 2.0 (1.9–2.1) | 35 (4.4); 3.1–6.2 | 223 (28.2); 25.1–31.5 | 293 (37.0); 33.7–40.5 | 187 (23.6); 20.7–26.8 | 53 (6.7); 5.1–8.7 | |
| 1.7 (1.7–1.8) | 18 (2.3); 1.4–3.6 | 151 (19.1); 16.4–22.0 | 293 (37.0); 33.7–40.5 | 258 (32.6); 29.4–36.0 | 71 (9.0); 7.1–11.2 |
Communication of nocebo-related effects.
| Communication | Values | 95% CI |
| Balance the positive features of the therapy with the negative ones | 403 (50.9) | 47.4–54.5 |
| Carefully explain the effects and the role played by the negative context | 226 (28.6) | 25.5–31.9 |
| Minimize negative information on nocebo-related effects by not reporting all the elements | 85 (10.7) | 8.7–13.2 |
| Do not say anything | 77 (9.7) | 7.8–12.1 |
| During the decision of the therapeutic plan | 338 (42.7) | 39.3–46.3 |
| During the administration of the therapy | 221 (27.9) | 24.9–31.2 |
| Do not communicate anything | 114 (14.4) | 12.1–17.1 |
| During the anamnesis | 56 (7.1) | 5.4–9.1 |
| During the formulation of the diagnosis | 45 (5.7) | 4.2–7.6 |
| During the clinical examination | 17 (2.1) | 1.3–3.5 |
Management of nocebo-related effects.
| Management of nocebo-related effects, | Values | 95% CI |
| Teach and train patient’s strategies to manage nocebo-related effects | 313 (39.6) | 36.2–43.1 |
| Optimize expectations toward treatment and nocebo-related effects | 196 (24.8) | 21.8–28.0 |
| Explain nocebo-related effects using illustrative methods (e.g., videos, figures, graphs and percentages) and simple language | 110 (13.9) | 11.6–16.6 |
| Present first the positive features of the treatment and then the negative ones | 71 (9.0) | 7.1–11.2 |
| Do not do anything | 46 (5.8) | 4.3–7.7 |
| Use pre-treatments with a reduced percentage of nocebo-related effects (e.g., active or inert treatment-test) | 32 (4.0) | 2.8–5.7 |
| Refer to evidence-based information on the Internet | 14 (1.8) | 1.0–3.0 |
| Adopt a gradual reduction of the treatment in a hidden way | 9 (1.1) | 0.6–2.2 |
| Evaluate and modify patient’s anxieties, doubts and expectations | 298 (37.7) | 34.3–41.2 |
| Use an empathic and authentic communication style | 233 (29.5) | 26.3–32.8 |
| Provide adequate information (e.g., pathology, diagnosis, treatment, adverse events) | 145 (18.3) | 15.7–21.2 |
| Investigate previous experiences of therapeutic failure | 38 (4.8) | 3.5–6.6 |
| Ask the patient to summarize the information provided to avoid misunderstanding | 34 (4.3) | 3.0–6.0 |
| Use images and narrative | 26 (3.3) | 2.2–4.8 |
| Ask the patient to give questions | 17 (2.1) | 1.3–3.5 |